Overview

A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia

Status:
Not yet recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm the safety and efficacy of Herombopag in tumors-associated thrombocytopenia
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.